MedCity News

Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder

When AI Gets Medicine Wrong, Who’s Liable?

As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care?

By Jenna Congdon

Opinion

Fifty Years of Pediatric Rheumatology, but Children Still Can’t Access the Treatments They Need

As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change.

By Mirah Gillespie-Taylor

MedCity Influencers

MedTech Commercialization Gap: Moving Beyond Technical Viability

What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem.

By Adam Hesse

Latest Video

Latest News

Physicians

Report: High Drug Costs Are Creating Hidden Burden for Physicians

When drug prices are too high for patients, physicians take on additional workload to find solutions. A newly released 2026 Physician Drug Cost Survey by RazorMetrics examined how prescription cost pressures affect physicians’ practices.

By Jenna Congdon

BioPharma, Pharma

Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipeline also spans immunological disorders, cardiovascular diseases and obesity, and neurodegeneration.

By Frank Vinluan

MedCity Influencers

AI Goes All In To Support Nursing Teams: Ambient Charting is Just the Start

The question is whether these AI tools will be another fragmented layer of technology or true assistants to help them spend more time on patient care.

By Sarah Visker

Health Tech

UHC, Cigna and Centene Sign On to New National Shared Credentialing Program

CertifyOS launched a shared credentialing program that allows providers to submit their information once for multiple health plans.

By Marissa Plescia

BioPharma, Pharma

Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact

Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs.

By Frank Vinluan

Where Will AI Deployment Benefit Payers the Most?

We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.

By MedCity News

MedCity Influencers, Opinion

From OpenNotes to “Doc Can I Record You?” Why Physicians Should Embrace Era of Accountability

Healthcare has a habit of embracing patient empowerment right up until patients become powerful.

By Sachin H. Jain

MedCity Influencers

Modernizing Medicare Advantage for the Next Generation of Seniors

The Centers for Medicare & Medicaid Services (CMS) took constructive steps in its 2027 final rule and rate announcement, particularly on payment integrity and quality measurement. But those steps are not the finish line. Policymakers should further modernize MA to strengthen competition, transparency and accountability. Here’s where to start.

By John Kao

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah

BioPharma, Pharma

Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease`

Roche reported the drug sefaxersen achieved statistically significant and clinically meaningful results in a Phase 3 test in immunoglobulin A nephropathy, or IgAN. This antisense oligonucleotide, which came from Ionis Pharmaceuticals, could offer advantages over other drugs currently available for treating this rare chronic disease of the kidneys.

By Frank Vinluan

Health Tech, Devices & Diagnostics

Digital generated image of multi layered dollar sign making swirl pattern.

Teal Health Secures $22M for At-Home HPV Cervical Cancer Screening Device

The Series A round was led by .406 Ventures, with support from Emerson Collective (managed by Yosemite), Forerunner, Serena Ventures and Japan-based MPower Partners.

By Marissa Plescia

Providers, Artificial Intelligence

Who is Abridge’s CEO Shiv Rao? No, Really…

At the annual South Asian Health Leaders Forum held in Boston last week, Shiv Rao talked candidly about his biography and how it propelled him to build Abridge

By Arundhati Parmar

MedCity Influencers

Female Doctor or Scientist Holds Test Tube in Laboratory, Advancing Healthcare Innovation with Research and Experimentation, Vector Flat Illustration

Innovation in Oncology: The Synergy of New and Old Drugs

Years of joint industry-academic engineering suggest that highly engineered single agents will not be the most effective treatments for solid tumors; the solution will be combining the right drugs and administering them in the right way.

By Jason Litten

Health Tech

Pelago Unveils New Behavioral Health Platform for Substance Use, Mental Health and Behavioral Addiction Care

Pelago launched a behavioral health platform that integrates substance use, mental health and behavioral addiction care, using AI-powered triage to connect patients with appropriate treatment.

By Marissa Plescia

How is Oracle Health’s Nurse AI Agent Different?

The Oracle Health Clinical AI Agent is unique in the way it’s embedded directly in the Oracle Health Foundation EHR, making it easier for nurses who don’t have to shift between tools used for separate tasks.

By Zoe Cunniffe

BioPharma, Pharma

Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds

Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren's disease. This fusion protein could compete against a Novartis antibody under an FDA review that could make it the first Sjögren's therapy.

By Frank Vinluan

MedCity Influencers

AI Workers Need a Probation Period, Not Just a Pilot

Healthcare leaders know how to test software. We don't yet have a shared playbook for onboarding agents expected to do a job end to end. That is the gap a probation period is meant to fill.

By Jost-Vincent Steiskal